1. Data on migration of the non-invasive breast cancer cell line, MCF-7 treated with Bevacizumab using Real Time Cell Analyzer (RTCA)
- Author
-
Layal El-Hajjar, Kazem Zibara, Jalal M. Kazan, Jamal El-Saghir, Marwan El-Sabban, Abdullah Shaito, and Nour Jalaleddine
- Subjects
genetic structures ,Bevacizumab ,Inflammation ,lcsh:Computer applications to medicine. Medical informatics ,RTCA ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer cell line ,Biochemistry, Genetics and Molecular Biology ,Medicine ,Research article ,lcsh:Science (General) ,skin and connective tissue diseases ,Migration ,030304 developmental biology ,Cell analyzer ,0303 health sciences ,Multidisciplinary ,business.industry ,Non invasive ,medicine.disease ,Metastatic breast cancer ,eye diseases ,MCF-7 ,Cancer research ,lcsh:R858-859.7 ,medicine.symptom ,business ,030217 neurology & neurosurgery ,lcsh:Q1-390 ,medicine.drug - Abstract
Bevacizumab or Avastin® (Av), the recombinant antibody targeting VEGF, improves progression-free but not overall survival of metastatic breast cancer patients due to development of Av resistance. We showed that Av-therapy-induced inflammatory microenvironment contributes to the refractoriness to Av treatment. Here we present data regarding the effect of Av treatment on migration of a non-invasive breast cancer cell line, MCF-7. The data presented hereis related to the research article “Bevacizumab induces inflammation in MDA-MB-231 breast cancer cell line and in a mouse model” (Hajjar et al., 2018). Keywords: Bevacizumab, MCF-7, Migration, RTCA
- Published
- 2019